The Amazing Old Nova Q Cygni: A Far Ultraviolet Synthetic Spectral Analysis

Q Cygni (Nova Cygni 1876) is the third oldest old novae (after WY Sge and V841 Oph) with a long orbital period of 10.08 hours and spectroscopic peculiarities in the optical including the presence of variable wind outflow revealed by optical P Cygni profiles in the HeI lines and H alpha beta (Kafka et al. 2003). We have carried out a synthetic spectral analysis of a far ultraviolet IUE archival spectrum of Q Cygni using our optically thick, steady state, accretion disk models and model white dwarf photospheres. We find that the accretion light of a luminous accretion disk dominates the FUV flux of the hot component with a rate of accretion 2-3 1.E-9 Msun/yr. We find that Q Cygni lies at a distance of 741 \pm 110 pc . The implications of our results for theoretical predictions for old novae are presented.Comment: PASP, August 201

Accretion and activity on the post-common-envelope binary RR~Cae

Current scenarios for the evolution of interacting close binaries - such as cataclysmic variables (CVs) - rely mainly on our understanding of low-mass star angular momentum loss (AML) mechanisms. The coupling of stellar wind with its magnetic field, i.e., magnetic braking, is the most promising mechanism to drive AML in these stars. There are basically two properties driving magnetic braking: the stellar magnetic field and the stellar wind. Understanding the mechanisms that drive AML therefore requires a comprehensive understanding of these two properties. RRCae is a well-known nearby (d=20pc) eclipsing DA+M binary with an orbital period of P=7.29h. The system harbors a metal-rich cool white dwarf (WD) and a highly active M-dwarf locked in synchronous rotation. The metallicity of the WD suggests that wind accretion is taking place, which provides a good opportunity to obtain the mass-loss rate of the M-dwarf component. We analyzed multi-epoch time-resolved high-resolution spectra of RRCae in search for traces of magnetic activity and accretion. We selected a number of well-known activity indicators and studied their short and long-term behavior. Indirect-imaging tomographic techniques were also applied to provide the surface brightness distribution of the magnetically active M-dwarf, and reveals a polar feature similar to those observed in fast-rotating solar-type stars. The blue part of the spectrum was modeled using a atmosphere model to constrain the WD properties and its metal enrichment. The latter was used to improve the determination of the mass-accretion rate from the M-dwarf wind. The presence of metals in the WD spectrum suggests that this component arises from accretion of the M-dwarf wind. A model fit to the WD gives Teff=(7260+/-250)K and logg=(7.8+/-0.1) dex with a metallicity of =(-2.8+/-0.1)dex, and a mass-accretion rate of dotMacc=(7+/-2)x1e-16Msun/yr.Comment: 14 pages, 7 Figures, 6 Table

"Dark Matter" in Accretion Disks

Using Spitzer Space Telescope photometric observations of the eclipsing, interacting binary WZ Sge, we have discovered that the accretion disk is far more complex than previously believed. Our 4.5 and 8 micron time series observations reveal that the well known gaseous accretion disk is surrounded by an asymmetric disk of dusty material with a radius approximately 15 times larger than the gaseous disk. This dust ring contains only a small amount of mass and is completely invisible at optical and near-IR wavelengths, hence consisting of "dark matter". We have produced a model dust ring using 1 micron spherical particles with a density of 3 g/cm$^3$ and with a temperature profile ranging from 700-1500K. Our discovery about the accretion disk structure and the presence of a larger, outer dust ring have great relevance for accretion disks in general, including those in other interacting binary systems, pre-main sequence stars, and active galaxies.Comment: 34 pages, 8 figures (3 in color). Accepted to Ap

Time-resolved measurement of single pulse femtosecond laser-induced periodic surface structure formation

Time-resolved diffraction microscopy technique has been used to observe the formation of laser-induced periodic surface structures (LIPSS) from the interaction of a single femtosecond laser pulse (pump) with a nano-scale groove mechanically formed on a single-crystal Cu substrate. The interaction dynamics (0-1200 ps) was captured by diffracting a time-delayed, frequency-doubled pulse from nascent LIPSS formation induced by the pump with an infinity-conjugate microscopy setup. The LIPSS ripples are observed to form sequentially outward from the groove edge, with the first one forming after 50 ps. A 1-D analytical model of electron heating and surface plasmon polariton (SPP) excitation induced by the interaction of incoming laser pulse with the groove edge qualitatively explains the time-evloution of LIPSS formation.Comment: 4 pages, 5 figure

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.

Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX) therapy and to assess cost implications from the commercial perspective. Methods: Adult RA patients with a new episode of GLM-IV or IFX treatment between January 1, 2014 and March 31, 2016 were identified from MarketScan databases and evaluated for maintenance infusion intervals and related costs of treatment. IFX and GLM-IV patients were matched 1:1 on index medication treatment duration, gender, payer type, prior biologic use, and post-index methotrexate use. Paid amounts for drugs and associated administration costs were applied to treatment group dosing patterns. Results: Final matched treatment groups included 547 GLM-IV and 547 IFX patients (mean age = 55-56 years). Mean (SD) follow-up was 609 (161) days for GLM-IV and 613 (163) days for IFX. Treatment duration was 396 (240) days for GLM-IV and 397 (239) days for IFX. Overall, 80% of GLM-IV and 39% of IFX maintenance infusions were given approximately every 8 weeks; and 6% of GLM-IV and 53% of IFX maintenance infusions occurred more frequently than every 8 weeks (P\u3c0.001). When weighting of the maintenance infusion interval was applied, the mean number of induction plus maintenance infusions during the first year of treatment was estimated at 7.03 for GLM-IV and 9.48 for IFX. From the commercial perspective, drug plus administration costs per infusion were $5,846 for GLM-IV and$5,444 for IFX with total annual cost of therapy for GLM-IV patients costing $10,507 less than that for IFX patients in the first year and$6,774 less than that for IFX patients in subsequent years. Conclusion: Annual GLM-IV drug plus administration costs for commercial health plans were significantly less than IFX in RA patients due to differences in real-world dosing and administration. © 2019 Ellis et al

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA). Methods: This was a single-center, non-interventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients completed the questionnaire comprising 30 questions centered on their experience receiving an intravenously administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and IV). Patients rated their level of agreement with statements regarding satisfaction with current IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using a 5-point Likert scale (1= strongly disagree, 5= strongly agree). Results: One hundred patients were enrolled and completed the survey; 66% were female and the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5. The proportion of patients with an “extremely favorable” perception of IV therapy increased from 33% to 71% following initiation of their current medication. Thirty-one patients had previously received SC therapies to treat their IA. Conclusion: These results demonstrated an overall favorable perception of IV therapy among this patient population. Patients previously treated with SC therapy also had a positive shift in the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for treatment options should be highly considered by the treating physician during or as part of a shared decision-making process. © 2017 Gaylis et al